Onyx Scientific is the CDMO division of Ipca Laboratories, specialising in small molecule drug substance development and GMP manufacturing. With MHRA-licensed UK facilities, we support projects from early candidate selection through preclinical and clinical development to commercial supply.
We offer comprehensive Chemistry, Manufacturing, and Controls (CMC) services, helping clients streamline development, reduce risk, and accelerate timelines. Our capabilities include custom synthesis, process research, route scouting, scale-up, analytical development, solid-state chemistry, polymorph screening, salt selection, stability studies, method development, and regulatory support — all designed to ensure high-quality outcomes at every stage.
A key strength is our dedicated solid-state and analytical chemistry teams, who expedite development and manage full-service outsourced projects to complement in-house capabilities. With extensive experience in lead optimisation, process intensification, and quality-by-design approaches, we help partners make informed, data-driven decisions.
Our pragmatic, fit-for-purpose approach focuses on rapid process development while maintaining a strategic view toward future GMP campaigns. As programs advance, we offer seamless scale-up through Phase I and II, with flexible options for commercial manufacture at Onyx or via our sister sites in the USA and India, providing a global network of expertise and supply security.
With a proven track record supporting biotech and pharma companies worldwide, Onyx Scientific combines agility, technical excellence, and end-to-end CMC services to deliver reliable, high-quality outcomes that accelerate drug development and bring innovative therapies to patients faster.
